Fundraising appeals for cancer treatment abroad have become a familiar feature of Kazakhstan’s social media landscape. A photograph, a medical report, a bank account number and a plea for help often signal a family’s decision that treatment outside the country offers the best chance of survival.
Whether that perception is justified remains one of the most sensitive questions facing Kazakhstan’s healthcare system.
According to the Ministry of Health, the incidence of malignant neoplasms in urban areas reached approximately 239 cases per 100,000 people in 2024, up from 230 a year earlier. Kazakhstan records one of the highest cancer incidence rates in Central Asia, ahead of Kyrgyzstan, Uzbekistan, Turkmenistan and Tajikistan, according to recent regional comparisons.
More than 30,000 new cancer cases are diagnosed in Kazakhstan each year, while thousands of people die annually from malignant tumors. Breast cancer is the most commonly diagnosed form of the disease, followed by colorectal and lung cancers. Lung cancer remains one of the leading causes of cancer-related mortality.
The burden of disease is not evenly distributed. The highest incidence rates are recorded in industrial regions such as Pavlodar, Karaganda, Kostanay, North Kazakhstan and East Kazakhstan. Specialists attribute the trend to a combination of environmental pollution, unhealthy lifestyles, population aging and, according to some experts, the long-term effects of the COVID-19 pandemic.
Kazakhstan’s leading oncologists generally reject the notion that treatment abroad is automatically better.
The country’s major oncology centers offer surgery, chemotherapy and radiation therapy using treatment protocols that largely correspond to international standards. Physicians at the National Research Oncology Center in Astana note that many patients who travel to Turkey or South Korea eventually receive treatment recommendations similar to those available in Kazakhstan, often at a much higher personal cost.
The difference, doctors and patients say, often lies in speed and service. Private clinics abroad can offer faster access to consultations, diagnostics and treatment, while patients frequently cite more personalized care and greater attention from medical staff. For families confronting a life-threatening diagnosis, such factors can become decisive.
At the same time, some limitations within Kazakhstan’s healthcare system are difficult to ignore.
The country’s bone marrow donor registry remains relatively small. In leukemia cases where no compatible donor can be found among relatives, patients often depend on international registries and may require treatment abroad. Organ transplantation from deceased donors also remains underdeveloped. In some cases of liver cancer, patients must travel to countries such as Belarus when no living donor is available.
Some of the latest targeted therapies and immunotherapy drugs are also not yet registered in Kazakhstan, although oncologists say new treatments are gradually being incorporated into clinical practice.
One of the most common complaints among patients with cancer in Kazakhstan concerns delays in diagnostics and treatment.
Kazakhstan’s healthcare system formally guarantees a so-called “green corridor” for oncology patients, under which no more than 30 days should pass between the initial suspicion of cancer and the start of treatment. In practice, however, access to high-tech diagnostic equipment remains uneven.
PET/CT scanners, a key tool in cancer diagnosis and treatment planning, are concentrated in a limited number of cities, including Astana, Almaty and Semey. Waiting times can be lengthy, and in oncology even a few weeks may affect treatment outcomes.
The cost of treatment abroad presents another challenge. A PET/CT examination can cost around $2,000 outside Kazakhstan, while radioiodine therapy may begin at $15,000-$20,000. Comprehensive treatment programs can cost significantly more, placing them beyond the reach of most families without savings or public fundraising campaigns.
Not all patients travel independently. According to Kazakhstan’s Ministry of Health, approximately 100 citizens are referred abroad for treatment each year when the required procedures are unavailable domestically. In 2025, around 80 patients, most of them children, received treatment in Turkey, Germany, Russia, Belarus and India through a state-funded program.
The program is administered through institutions affiliated with the Social Health Insurance Fund and costs the state more than $2 million annually.
At the same time, Kazakhstan is seeking to position itself as a regional medical hub. Health Minister Akmaral Alnazarova has said that patients from China, India and Turkey already travel to Kazakhstan for treatment. Several hospitals in Astana have obtained Joint Commission International accreditation, and authorities are planning a new oncology center equipped with proton therapy technology.
Experts caution, however, that advanced infrastructure alone will not be enough. Developing expertise in cutting-edge cancer treatment requires years of training and close cooperation with international specialists.
Kazakhstan’s oncology system presents a complex picture. The country provides free access to expensive cancer medications, offers internationally recognized treatment methods and has expanded cooperation with foreign medical institutions. Survival rates have improved, and investments in specialized oncology facilities continue.
Yet significant challenges remain. Limited transplant capacity, donor shortages, delays in diagnostics and a persistent lack of public trust continue to drive some patients to seek treatment elsewhere.
For many families, the decision to go abroad is not purely medical. It is also emotional; an attempt to do everything possible when confronted with a frightening diagnosis.
Until Kazakhstan can consistently combine modern treatment, rapid access to care and a patient-centered approach, fundraising campaigns for treatment in foreign clinics are likely to remain a recurring feature of public life.
